Is it safe to get UTI antibiotics from a pharmacist without seeing a GP?

For an uncomplicated UTI — lower urinary tract symptoms (dysuria, frequency, urgency) in an otherwise healthy, non-pregnant woman without fever or flank pain — pharmacist prescribing in a structured program like the Tasmanian pilot is a reasonable option. The pilot showed no formal adverse outcome reports and an 88% patient-reported improvement rate. The concern the RACGP raises is not that pharmacists are unsafe, but that the evaluation methodology does not allow us to confirm the clinical outcome data. If you have any fever, back or flank pain, nausea, are pregnant, or your symptoms do not improve within 48 hours, see a GP or attend urgent care rather than relying on a pharmacist consultation alone.

Why does the RACGP oppose pharmacists treating UTIs?

The RACGP's stated concern is not that pharmacists cannot manage UTIs — it is that the Tasmanian pilot evaluation lacked adequate outcome data. Only 1.8% of patients who received care through the pilot provided feedback; diagnostic accuracy, confirmed recovery, and long-term antibiotic resistance patterns were not measured. RACGP President Dr Michael Wright put it clearly: 'Counting consultations and prescriptions tells us how much care was delivered. It doesn't tell us whether patients got better.' That is a methodological criticism, not an argument against the model per se.

What are the red flags that mean I should see a GP and not a pharmacist for urinary symptoms?

Fever, chills, back or flank pain, nausea or vomiting alongside urinary symptoms — these suggest the infection may have ascended to the kidneys (pyelonephritis) rather than remaining in the lower urinary tract. Pyelonephritis requires a GP assessment, urine culture, and potentially IV antibiotics or hospital admission — it is not appropriate for pharmacist-only management. Other reasons to see a GP: pregnancy, recurrent UTIs (more than three per year), recent instrumentation of the urinary tract, immunosuppression, or symptoms that do not improve within 48 hours of starting antibiotics.

UTI pharmacy pilot wins expansion — but what about the outcomes?

Urinary tract infections are one of the most common reasons women in their 30s, 40s, and 50s see a GP. They are also one of the most reliably underserved. The 10-minute appointment, the wait for the next available booking, the TGA-regulated requirement for a prescription — for a condition that is frequently uncomplicated and for which the treatment protocol has not changed meaningfully in decades, the friction is real and it falls disproportionately on women.

The Tasmanian UTI pharmacy pilot ran for 12 months from March 2024, allowing pharmacists to prescribe antibiotics for uncomplicated UTIs without a referral. An evaluation has now recommended that the arrangement be made permanent — and potentially expanded nationally. The RACGP is pushing back. Both positions deserve a careful read.

What the pilot actually showed

Over 12 months, 6,534 episodes of care were delivered through the pilot. Ninety-one percent of patients received antibiotics. Average consultation time was 10 minutes. Of those who completed the satisfaction survey, 88% reported feeling better. Twenty-five percent required follow-up care, the majority with GPs.

No formal adverse outcome reports were filed. No increased TGA medication-related adverse reaction reports were noted. On the face of it, a significant volume of care was delivered, patients reported positive experiences, and the burden on GP appointments was reduced.

The evaluation recommends making the arrangement permanent in Tasmania, eliminating mandatory follow-up requirements, and providing safety advice to patients including red flags and when to seek further care.

The methodological problem the RACGP is naming

The RACGP’s objection is specific and it is legitimate: only 120 patients responded to the satisfaction survey. That is 1.8% of the 6,534 who received care through the pilot.

RACGP President Dr Michael Wright put the critique directly: “Counting consultations and prescriptions tells us how much care was delivered. It doesn’t tell us whether patients got better.”

This is not obstructionism. It is the standard question that any evidence-based evaluation should answer before recommending permanent policy change. What the pilot measured: consultation volumes, prescription rates, patient satisfaction, cost-reduction estimates, and pressure relief on GP appointment supply. What the pilot did not measure: diagnostic accuracy (were these confirmed UTIs or other urological symptoms?), confirmed clinical recovery, antibiotic resistance patterns in those treated, or outcomes in the 25% who required GP follow-up.

A 1.8% survey return rate in a health intervention evaluation is not sufficient to draw conclusions about population-level clinical outcomes. The 88% of respondents who reported feeling better is good news, but it is not the same as knowing 88% of 6,534 patients recovered without complication.

Both and

Here is what is true on both sides.

The access problem is real. Women with uncomplicated UTIs navigate a healthcare system that requires an appointment, often a wait, and the cost of a GP consultation for a condition where the treatment is a standard antibiotic course they have taken before. Streamlining that pathway serves a genuine need, and models where pharmacists play an expanded prescribing role are working well in comparable health systems.

And the evaluation methodology is genuinely insufficient to say the clinical outcomes match the access gains. The pilot showed that pharmacists can deliver a large volume of UTI care efficiently and that patients report feeling better. It did not show — because it did not measure — whether the right patients were being treated, whether resistance patterns were affected, or whether the 25% who needed GP follow-up had a worse outcome than if they had presented to general practice initially.

The antimicrobial stewardship piece

This is the part of the debate that often gets lost in the access-versus-scope-of-practice framing: antibiotic prescribing decisions in UTI management have antimicrobial stewardship implications. Appropriate antibiotic selection, duration, and follow-up matter both for individual recovery and for community-level resistance patterns. A pilot that does not track resistance outcomes cannot claim to have answered the antimicrobial stewardship question.

That is not a reason to reject pharmacist prescribing for UTIs — it is a reason to collect the data before declaring the policy a success.

2 cents

If you are a woman who gets UTIs and you are in a jurisdiction where pharmacist prescribing is available or being considered: it is a reasonable option for uncomplicated lower urinary tract symptoms when you have no fever, no flank pain, are not pregnant, and have no complicating factors. If your symptoms do not resolve within 48 hours of starting antibiotics, see a GP.

For the policy question: the expansion deserves better evidence than a 1.8% survey return rate before it is declared a clinical success. The RACGP is asking the right question. So is the government, if it genuinely wants to know whether the care delivered was good care — not just a lot of care.

Verdict: maybe — the access win is real. The clinical evidence is not yet there to match it.